CiVentiChem, a CDMO, has completed a new facility, significantly expanding its manufacturing capacity by 300%. This state-of-the-art facility will focus on producing Regulatory Starting Materials (RSMs) and intermediates to support small molecule clinical and commercial needs.
 
“It’s a major evolution for the company,” said Bhaskar Venepalli, CEO of CiVentiChem. “The decision to invest in a second manufacturing plant was driven by our customers and recent international developments. We’ve seen an increasing number of clients seeking alternative manufacturers outside of China for RSMs and intermediates. We’re thrilled to support the growing manufacturing needs of our clients.”
 
Founded in North Carolina in 1994, the company initially offered medicinal chemistry and FTE services. In 2001, CiVentiChem opened their first R&D facility in Hyderabad, India. CiVentiChem expanded to larger scale manufacturing in 2009, manufacturing RSMs for clinical programs and three commercial programs.